Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of YKYY018 inhalation solution in adults with RSV infection
CTR20263412Phase 2Active
- Sponsor
- Yuekang Kechuang
- Start
- Sep 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of YKYY018 in respiratory syncytial virus disease (RSV), sponsored by Yuekang Kechuang. Started Sep 2026; status: active.
02
Drugs
YKYY018
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on CTR20263412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263412.